Cutanos

Description

Cutanos develops LC-TDS, a ligand-based delivery platform that uses langerin-specific glycomimetic ligands on lipid nanoparticles to selectively deliver mRNA to Langerhans cells for skin-directed mRNA delivery.

Cutanos is located in the Vienna ecosystem.

Related

• CPTxCPTx develops in vivo CAR-T genetic medicines using an immune-silent ssDNA platform and non-viral lipid nanoparticle delivery to encode…
• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• CaszymeCaszyme provides customized CRISPR solutions using a flexible platform and expertise in nucleases, mRNA, protein engineering, and evolution…
• CCeraVxCeraVx develops ceramic CeraMaps microneedle patches for intradermal delivery of vaccines and medicines, using biocompatible, inert…
• SciRhomSciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF…
• Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…
• SarcuraSarcura develops a miniaturized, autonomous device platform for cell therapy manufacturing, using control intelligence, semiconductor chip…
• DiabeloopDiabeloop develops automated, personalized insulin delivery software powered by artificial intelligence, using compatible continuous…
• NanoPhoriaNanoPhoria develops an inhaled Nano-in-Micro delivery platform and formulations to deliver therapeutic peptides and RNAs for…